INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. on April 10, 2017. The company is incorporated in Nevada and operates in the assisted reproductive technology sector. The report primarily addresses a change in the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The company describes itself as being in its infancy and underfunded. No financial statements are included in this specific report.
Material Changes
- Board Election: On April 7, 2017, the Board of Directors unanimously elected Dr. Kevin Doody to fill the vacancy left by the resignation of Claude Ranoux.
- Board Composition: The Board currently consists of three directors. No board committees have been established due to the company's early stage.
Management Commentary and Risks
Management highlighted Dr. Doody's extensive credentials, including his role as President of the Society for Assisted Reproductive Technology (SART) and Medical Director for CARE Fertility/Effortless IVF. Dr. Doody's clinic was the first to adopt the INVOcell Intravaginal Culture System following FDA clearance. The filing explicitly states there are no compensatory arrangements, contracts, or understandings between Dr. Doody and existing directors regarding his election. Additionally, no related party transactions exceeding $120,000 have occurred since January 1, 2016.
Investor Verification Checklist
- Verify the resignation date and circumstances of former director Claude Ranoux.
- Confirm the company's current cash runway and funding status given the "underfunded" disclosure.
- Review the company's latest 10-K or 10-Q for detailed financial performance metrics not present in this 8-K.
- Monitor future filings for the establishment of board committees as the company grows.